Statins and coronary artery bypass graft surgery: preoperative and postoperative efficacy and safety

被引:50
|
作者
Kulik, Alexander [1 ]
Ruel, Marc [1 ]
机构
[1] Univ Ottawa, Univ Heart Inst, Ottawa, ON, Canada
关键词
coronary artery bypass graft Surgery; coronary artery disease; efficacy; lipids; safety; saphenous vein graft disease; statins; HMG-COA-REDUCTASE; LIPID-LOWERING-THERAPY; MUSCLE-CELL-PROLIFERATION; COENZYME-A REDUCTASE; SYSTEMIC INFLAMMATORY RESPONSE; ADVERSE CARDIAC EVENTS; ATRIAL-FIBRILLATION; SECONDARY PREVENTION; MYOCARDIAL-INFARCTION; COLESTIPOL-NIACIN;
D O I
10.1517/14740330903188413
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: In patients with native coronary artery disease, strong evidence supports the use of statins to reduce the risk of recurrent cardiovascular events and improve survival. However, for patients undergoing coronary artery bypass graft surgery (CABG), statins appear to be underutilized, and concerns have been raised regarding their perioperative safety. Objective: The goal of this systematic review is to evaluate the safety and efficacy of statin therapy before and after coronary surgical revascularization. Methods: A systematic review was performed to retrieve relevant articles from the Medline database published between 1987 and January 2009. Results: Administered before CABG, statins have been demonstrated to reduce perioperative mortality, stroke and atrial fibrillation. Preoperative statin therapy also reduces the systemic inflammatory response associated with cardiopulmonary bypass. Following CABG, statins inhibit saphenous vein graft disease and the progression of atherosclerosis in native coronary arteries. In addition, postoperative statins reduce the recurrence of cardiovascular events and improve all-cause mortality. High-intensity lipid reduction to achieve low-density lipoprotein levels to 70 mg/dl may benefit post-CABG patients, but this has yet to be evaluated prospectively. Adverse effects related to perioperative statin therapy seem to be extremely rare, and little data are available to support the practice of withholding statin therapy before or after surgery. Conclusion: Numerous studies have demonstrated that statins improve the outcomes of patients undergoing CABG. The benefits seem to outweigh the risks associated with their use, both in the preoperative and postoperative period. In the absence of contra indications, essentially all CABG patients are candidates for life-long statin therapy that ideally should be started before surgery. The optimal postoperative statin regimen remains unknown and should be the subject of future study.
引用
收藏
页码:559 / 571
页数:13
相关论文
共 50 条
  • [41] Is preoperative fibrinogen predictive for postoperative bleeding after coronary artery bypass grafting surgery?
    Bolliger, Daniel
    Gonsahn, Meredith
    Levy, Jerrold H.
    Williams, Willis H.
    Tanaka, Kenichi A.
    TRANSFUSION, 2009, 49 (09) : 2006 - 2007
  • [42] PREOPERATIVE DETERMINANTS OF POSTOPERATIVE COSTS ASSOCIATED WITH CORONARY-ARTERY BYPASS-SURGERY
    SMITH, LR
    MOLTER, BS
    MILANO, CA
    ELBEERY, JR
    SABISTON, DC
    SMITH, PK
    CIRCULATION, 1993, 88 (04) : 387 - 387
  • [43] Coronary artery bypass graft surgery in women
    Fox, AA
    Nussmeier, NA
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2004, 18 (03) : 344 - 352
  • [44] Outcomes of coronary artery bypass graft surgery
    Hawkes, Anna Louise
    Nowak, Madeleine
    Bidstrup, Benjamin
    Speare, Richard
    VASCULAR HEALTH AND RISK MANAGEMENT, 2006, 2 (04) : 477 - 484
  • [45] Efficacy and Safety of Dual Antiplatelet Therapy on Graft Patency After Coronary Artery Bypass Graft Surgery: A Randomized Controlled Trial
    Abdi, Seifollah
    Momtahen, Mahmood
    Bassiri, Hossein-Ali
    Shafiei, Ali
    Sadeghipour, Parham
    Madani, Mohsen
    Bakhshandeh, Hooman
    IRANIAN HEART JOURNAL, 2020, 21 (01): : 6 - 16
  • [46] Preoperative hemostatic testing and the risk of postoperative bleeding in coronary artery bypass surgery patients
    Rafiq, Sulman
    Johansson, Par I.
    Kofoed, Klaus F.
    Olsen, Peter S.
    Steinbruchel, Daniel A.
    JOURNAL OF CARDIAC SURGERY, 2016, 31 (09) : 565 - 571
  • [47] Coronary artery bypass graft surgery: an update
    Lafci, Gokhan
    Cagli, Kerim
    Ozcan, Firat
    TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2014, 22 (01): : 211 - 215
  • [48] To be or not to be on: aspirin and coronary artery bypass graft surgery
    Gupta, Aashray K.
    Kovoor, Joshua G.
    Leslie, Alasdair
    Litwin, Peter
    Stretton, Brandon
    Zaka, Ammar
    Kovoor, Pramesh
    Bacchi, Stephen
    Bennetts, Jayme S.
    Maddern, Guy J.
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2024, 11
  • [49] SAFETY OF INTRAVENOUS KETOROLAC POST-CORONARY ARTERY BYPASS GRAFT SURGERY
    Montero, Jennifer
    Semanco, Michael
    CRITICAL CARE MEDICINE, 2025, 53 (01)
  • [50] Safety of low-dose aprotinin in coronary artery bypass graft surgery
    Kluth, Mario
    Lueth, Jan U.
    Zittermann, Armin
    Lanzenstiel, Markus
    Koerfer, Reiner
    Inoue, Kazuo
    DRUG SAFETY, 2008, 31 (07) : 617 - 626